Abstract Library

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#4539 Single-nucleus profiling of the tumour microenvironment in SI-NET patients

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are frequently present as multiple synchronous primary tumours in the small bowel. They are thought to arise from enterochromaffin (EC) cells in the gut, which account for less than 1% of the intestinal epithelium. Previously reported lack of shared somatic driver alterations in SI-NETs suggests that other, non-genetic mechanisms are likely involved in their tumorigenesis.

Conference:

Presenting Author: Mäkinen N

Authors: Mäkinen N, Kasai Y, Kim G, Thirlwell C, Nakakura E,

Keywords: small intestinal NET, tumour microenvironment, single-nucleus sequencing,

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,

#4166 Characterising the tumor microenvironment of multifocal small intestinal NETs

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are thought to arise from enterochromaffin cells of the gut, often with multiple synchronous primary tumors. Recently, we showed that synchronous primary tumors from the same SI-NET patient display distinct somatic mutational profiles, suggesting that these tumors originate independently, despite few clear driver mutations. Thus, new mechanistic insights into multifocal SI-NETs are urgently needed.

Conference:

Presenting Author:

Authors: Mäkinen N, Lee I, Dohlman A, Gao T, Zhang Z,

Keywords: small intestinal NET, tumor microenvironment, tumor microbiome,

#4129 Validation of a radiomics model to predict symptoms complications from small intestinal NET mesenteric metastases – Preliminary report

Introduction: The development of mesenteric metastases and associated mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NET) can cause significant complications and have implications in patients’ survival. CT is suboptimal for accurate assessment of the degree of fibrosis and prediction of complications. A better model is needed, therefore, in order to select patients who may benefit from a prophylactic surgical approach in the mesentery. Recently the promising role of a radiomics model was shown as a predictive tool for development of complications of mesenteric metastases/fibrosis in 68 patients.

Conference:

Presenting Author:

Authors: von Stempel C, Blazevic A, Starmans M, d' Afflitto M, de Herder W,

Keywords: small intestinal neuroendocrine tumor, mesenteric fibrosis, complications, radiomics,